{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:36:48Z","timestamp":1793943408411,"version":"4.8.0"},"reference-count":168,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.pharmthera.2025.108808","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T16:56:13Z","timestamp":1738774573000},"page":"108808","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["From barbiturates to ganaxolone: The importance of chirality in drug development and in understanding the actions of old and new antiseizure medications"],"prefix":"10.1016","volume":"268","author":[{"given":"Meir","family":"Bialer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Perucca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2025.108808_bb0005","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJM199608293350901","article-title":"Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International primary pulmonary hypertension study group","volume":"335","author":"Abenhaim","year":"1996","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0010","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1002\/cmdc.201900367","article-title":"Chirality as an important factor for the development of new antiepileptic drugs","volume":"14","author":"Abram","year":"2019","journal-title":"ChemMedChem"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0015","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/nrd915","article-title":"Putting chirality to work: The strategy of chiral switches","volume":"1","author":"Agranat","year":"2002","journal-title":"Nature Review Drug Discovery"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0020","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/nrd3657-c1","article-title":"The predicated demise of racemic new molecular entities is an exaggeration","volume":"11","author":"Agranat","year":"2012","journal-title":"Nature Review Drug Discovery"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0025","doi-asserted-by":"crossref","unstructured":"Andersen K. E., Braestrup, C., Gr\u00f8nwald, F. C., J\u00f8rgensen, A.S, Nielsen, E. B,. Sonnewald, U., et al. (1993). The synthesis of novel GABA uptake inhibitors. 1. Elucidation of the structure-activity studies leading to the choice of (R)-1-[4,4-bis(3-methyl-2-thienyl)-3-butenyl]-3-piperidinecarboxylic acid (tiagabine) as an anticonvulsant drug candidate. Journal of Medicinal Chemistry 36,1716\u20131725.","DOI":"10.1021\/jm00064a005"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0030","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0920-1211(94)90001-9","article-title":"Stereoselective pharmacokinetics of stiripentol: An explanation for the development of tolerance to anticonvulsant effect","volume":"18","author":"Arends","year":"1994","journal-title":"Epilepsy Research"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0035","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/BF00541922","article-title":"Stereochemistry, a basis for sophisticated non-sense in pharmacokinetics and clinical pharmacology","volume":"26","author":"Ariens","year":"1984","journal-title":"European Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0040","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/BF00265897","article-title":"Racemic therapeutics\u2014ethical and regulatory aspects","volume":"41","author":"Ari\u00ebns","year":"1991","journal-title":"European Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0045","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/0165-6147(93)90033-G","article-title":"Nonchiral, homochiral and composite chiral drugs","volume":"14","author":"Ari\u00ebns","year":"1993","journal-title":"Trends in Pharmacological Sciences"},{"issue":"Suppl. 192","key":"10.1016\/j.pharmthera.2025.108808_bb0050","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1600-0404.2011.01596.x","article-title":"Mechanism of action of vigabatrin: Correcting misperception","volume":"124","author":"Ben Menachem","year":"2011","journal-title":"Acta Neurorologica Scandinavica"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0055","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1021\/jm980627g","article-title":"Anticovulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives","volume":"42","author":"Benes","year":"1999","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0060","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1212\/WNL.4.2.116","article-title":"Mebaral as an anticonvulsant","volume":"4","author":"Berris","year":"1954","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0065","series-title":"Antiepileptic Drugs","first-page":"459","article-title":"Oxcarbazepine; chemistry, biotransformation, pharmacokinetics and drug interactions","author":"Bialer","year":"2002"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0070","series-title":"The treatment of epilepsy","first-page":"447","article-title":"Eslicarbazepine acetate","author":"Bialer","year":"2015"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0075","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1111\/epi.17376","article-title":"Progress report on new antiepileptic drugs: A summary of the sixteenth Eilat conference on new antiepileptic drugs and devices (EILAT XVI). II. Drugs in more advanced clinical development","volume":"63","author":"Bialer","year":"2022","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0080","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1111\/epi.18075","article-title":"Progress report on new antiepileptic drugs: A summary of the seventeenth Eilat conference on new antiepileptic drugs and devices (EILAT XVII). II. Drugs in more advanced clinical development","volume":"65","author":"Bialer","year":"2024","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0085","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/j.1528-1167.2012.03519.x","article-title":"Pharmacokinetics and drug interactions of eslicarbazepine acetate","volume":"53","author":"Bialer","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0090","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/sj.bjp.0704327","article-title":"Molecular targets for cannabidiol and its synthetic analogues: Effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide","volume":"134","author":"Bisogno","year":"2001","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0095","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1124\/molpharm.121.000305","article-title":"Differential enantiomer-specific signaling of cannabidiol at CB (1) receptors","volume":"102","author":"Bosquez-Berger","year":"2022","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0100","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1016\/0006-2952(68)90128-7","article-title":"Verteilung, narkotischer wirksamkeit und metabolischer elimination der optischen antipoden von methylphenobarbital","volume":"17","author":"Buch","year":"1968","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0105","first-page":"709","article-title":"Stereospecificity of anesthetic activity, distribution, inactivation and protein binding of the optical antipodes of two N-methylated barbiturates","volume":"176","author":"Buch","year":"1970","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0110","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1177\/1060028019856008","article-title":"Stiripentol: A novel antiseizure medication for the management of Dravet syndrome","volume":"53","author":"Buck","year":"2019","journal-title":"Annales of Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0115","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0022-3565(25)05076-1","article-title":"Quantitative studies of the metabolic fate of mephobarbital (N-methyl phenobarbital)","volume":"106","author":"Butler","year":"1952","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0120","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/BF03189414","article-title":"Pharmacokinetics of fenfluramine enantiomers in man","volume":"4","author":"Caccia","year":"1979","journal-title":"European Journal of Drug Metabolism and Pharmacokinetics"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0125","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/BF00547426","article-title":"Pharmacokinetics of fenfluramine and norfenfluramine in volunteers given D-and DL-fenfluramine for 15 days","volume":"9","author":"Caccia","year":"1985","journal-title":"European Jourmal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0130","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/j.1528-1167.2012.03495.x","article-title":"Successful use of fenfluramine as an add-on treatment for Dravet syndrome","volume":"53","author":"Ceulemans","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0135","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1097\/00000542-200112000-00029","article-title":"Stereospecific effect of pregabalin on ectopic afferent discharges and neuropathic pain induced by sciatic nerve ligation in rats","volume":"95","author":"Chen","year":"2001","journal-title":"Anesthesiology"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0140","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/14737175.2019.1593142","article-title":"Stiripentol for the treatment of seizures associated with Dravet syndrome","volume":"19","author":"Chiron","year":"2019","journal-title":"Expert Review Neurotherapeutics"},{"issue":"Suppl. 2","key":"10.1016\/j.pharmthera.2025.108808_bb0145","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1528-1167.2011.03007.x","article-title":"The pharmacologic treatment of Dravet syndrome","volume":"52","author":"Chiron","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0150","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1021\/jm9508705","article-title":"Synthesis and anticonvulsant activity of N-benzyl-2-acetamidopropionamide derivatives","volume":"39","author":"Choi","year":"1996","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0155","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0022-3565(25)28758-4","article-title":"Metabolism and anticonvulsant properties of mephobarbital and phenobarbital in rats","volume":"176","author":"Craig","year":"1971","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0160","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1021\/acsptsci.2c00151","article-title":"The quest for secondary pharmaceuticals: Drug repurposing\/chiral\u2013switches combination strategy","volume":"6","author":"D\u2019Acquarica","year":"2023","journal-title":"ACS Pharmacology and Translational Science"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0165","doi-asserted-by":"crossref","unstructured":"Dooley, D.J., Taylor, C.P., Donevan, S., & Feltner, D. (2007) Ca2+ channel alpha2delta ligands: Novel modulators of neurotransmission. Trends in Pharmacological Sciences, 28, 75\u201382.","DOI":"10.1016\/j.tips.2006.12.006"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-2490(96)80003-7","article-title":"Stereochemical aspects of drug action and disposition","volume":"28","author":"Eichelbaum","year":"1996","journal-title":"Advances in Drug Research"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0175","series-title":"Program and Abstract Book, Madrid, Spain, 5\u20138 May 2024","author":"EILAT XVII","year":"2024"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0185","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1111\/epi.17598","article-title":"Comparative activity of the enantiomers of fenfluramine and norfenfluramine in rodent seizure models, and relationship with their concentrations in plasma and brain","volume":"64","author":"Erenburg","year":"2023","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0180","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1111\/epi.17846","article-title":"Pharmacokinetics of d- and l-norfenfluramine following their administration as individual enantiomers in rats","volume":"65","author":"Erenburg","year":"2024","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0190","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25052522","article-title":"A stereoselective analysis of the antiseizure activity of fenfluramine and norfenfluramine in mice; is l-norfenfluramine a better follow-up compound to racemic fenfluramine?","volume":"25","author":"Erenburg","year":"2024","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0195","unstructured":"European Medicines Agency (1993). Investigation of chiral active substances. Date of entry into force. April 1994. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/investigation-chiral-active-substances_en.pdf (accessed June 3, 2024)."},{"key":"10.1016\/j.pharmthera.2025.108808_bb0200","unstructured":"European Medicines Agency (1998). Committee for Veterinary Medicinal Products. Investigation of chiral active substances. Date of coming into operation: I. January 1998. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/note-guidance-investigation-chiral-active-substances_en.pdf (accessed June 3, 2024)."},{"key":"10.1016\/j.pharmthera.2025.108808_bb0205","unstructured":"European Medicines Agency (2007). Scientific discussion (Diacomit). Committee for Medicinal Products for Human Use (CHMP). Available at: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-discussion\/diacomit-epar-scientific-discussion_en.pdf (accessed July 9, 2024)."},{"key":"10.1016\/j.pharmthera.2025.108808_bb0210","unstructured":"European Medicines Agency (2020). Committee for Medicinal Products for Human Use (CHMP). Fintepla International non-proprietary name: fenfluramine (Public Assessment Report), EMA\/639853\/2020 Available at: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/fintepla-epar-public-assessment-report_en.pdf (accessed July 8, 2024)."},{"key":"10.1016\/j.pharmthera.2025.108808_bb0215","unstructured":"Fintepla. Prescribing information (last updated December 2023). Available at: https:\/\/www.ucb-usa.com\/fintepla-prescribing-information.pdf (accessed July 9, 2024)."},{"key":"10.1016\/j.pharmthera.2025.108808_bb0220","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0026-895X(24)26444-0","article-title":"Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine","volume":"57","author":"Fitzgerald","year":"2000","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0225","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1124\/dmd.109.030593","article-title":"Pharmacokinetics of the monohydroxy derivative of oxcarbazepine and its enantiomers after a single intravenous dose given as racemate compared to a single oral dose of oxcarbazepine","volume":"39","author":"Flesch","year":"2011","journal-title":"Drug Metabolism and Disposition"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0230","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/chir.530040513","article-title":"FDA\u2019s policy statement for the development of new Stereoisomeric drugs","volume":"4","author":"Food and Drug Administration (U.S.)","year":"1992","journal-title":"Chirality"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0235","author":"Food and Drug Administration (U.S.)"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0240","unstructured":"Food and Drug Administration (U.S.) (2008). Center for Drug evaluation and research: Application number: 22-006, clinical pharmacology and biopharmaceutics review(s) Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2009\/022006s000_ClinPharm.pdf (accessed July 23, 2024)."},{"key":"10.1016\/j.pharmthera.2025.108808_bb0245","unstructured":"Food and Drug Administration (U.S.) (2009). Center for drug evaluation and research: Application number 22-006, medical reviews(s). Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2009\/022006s000_MedR.pdf (accessed May 24, 2024)."},{"key":"10.1016\/j.pharmthera.2025.108808_bb0250","unstructured":"Food and Drug Administration (U.S.) (2016). Sabril (vigabatrin). Available at: https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/sabril-vigabatrin#:~:text=Sabril%20(vigabatrin)%2C%20an%20anticonvulsant,spasms%2C%20a%20form%20of%20epilepsy (accessed July 20, 2024)."},{"key":"10.1016\/j.pharmthera.2025.108808_bb0255","article-title":"Center for Drug evaluation and research: Application number 206709Orig1s000 207223Orig1s000","author":"Food and Drug Administration (U.S.)","year":"2017","journal-title":"Clinical Pharmacology and Biopharmaceutics Review(s)"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0260","article-title":"Center for Drug evaluation and research: Application number 206709Orig1s000 207223Orig1s000","author":"Food and Drug Administration (U.S.)","year":"2018","journal-title":"Clinical Reviews(s)."},{"key":"10.1016\/j.pharmthera.2025.108808_bb0265","article-title":"Center for Drug evaluation and research: Application number 206709Orig1s000 207223Orig1s000","author":"Food and Drug Administration (U.S.)","year":"2018","journal-title":"Other Review(s)."},{"key":"10.1016\/j.pharmthera.2025.108808_bb0270","article-title":"Center for Drug evaluation and research: Application number 206709Orig1s000 207223Orig1s000","author":"Food and Drug Administration (U.S.)","year":"2018","journal-title":"Summary Review"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0275","article-title":"Center for Drug evaluation and research: Application number 212102Orig1s000","author":"Food and Drug Administration (U.S.)","year":"2020","journal-title":"Non-Clinical Review(s)"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0280","article-title":"Center for Drug evaluation and research: Application number 212102Orig1s000","author":"Food and Drug Administration (U.S.)","year":"2020","journal-title":"Clinical Pharmacology and Biopharmaceutics Review(s)"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0285","article-title":"Center for Drug evaluation and research: Application number 212102Orig1s000","author":"Food and Drug Administration (U.S.)","year":"2020","journal-title":"Clinical Review(s)"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0290","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s40265-023-01881-w","article-title":"Fenfluramine: A review in Dravet and Lennox-Gastaut syndromes","volume":"83","author":"Frampton","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108442","article-title":"Cannabidiol in the treatment of epilepsy: Current evidence and perspectives for further research","volume":"185","author":"Franco","year":"2021","journal-title":"Neuropharmacology"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2025.108808_bb0300","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1185\/03007997909117488","article-title":"Biochemical pharmacology of the anorectic drug fenfluramine: A review","volume":"6","author":"Garattini","year":"1979","journal-title":"Current Medical Research and Opinion"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0305","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0014-2999(01)00800-7","article-title":"GABAergic blockade of cocaine-associated cue-induced increases in nucleus accumbens dopamine","volume":"41","author":"Gerasimov","year":"2001","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0310","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejphar.2011.04.064","article-title":"Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: Relationship to anti-convulsant properties","volume":"664","author":"Gillard","year":"2011","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2003.08.032","article-title":"Binding characteristics of [3H]Ucb30880 to levetiracetam binding sites in rat brain","volume":"478","author":"Gillard","year":"2003","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0320","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1056\/NEJMoa0902014","article-title":"Ethosuximide, valproic acid and lamotrigine in childhood absence epilepsy","volume":"362","author":"Glauser","year":"2010","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0325","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/0006-2952(71)90494-1","article-title":"Tolerance to the hypnotic effect of 1-methylphenobarbital induced by its nonhypnotic stereoisomer","volume":"20","author":"Gordis","year":"1971","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0330","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0014-2999(92)90855-X","article-title":"ucb L059, a novel anti-convulsant drug: Pharmacological profile in animals","volume":"222","author":"Gower","year":"1992","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0335","article-title":"Zebrafish studies identify serotonin receptors mediating antiepileptic activity in D ravet syndrome. Brain","volume":"1","author":"Griffin","year":"2019","journal-title":"Communications"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0340","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/clpt.1988.194","article-title":"Pharmacokinetics of vigabatrin: Implications of creatinine clearance","volume":"44","author":"Haegele","year":"1988","journal-title":"Clinical Pharmacology and Therapeutics."},{"key":"10.1016\/j.pharmthera.2025.108808_bb0345","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/clpt.1986.227","article-title":"Kinetics of the enantiomers of vigabatrin after an oral dose of the racemate or the active S-enantiomer","volume":"40","author":"Haegele","year":"1986","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0350","doi-asserted-by":"crossref","DOI":"10.3390\/ph15020240","article-title":"Chiral switch: Between therapeutical benefit and marketing strategy","volume":"15","author":"Hancu","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0355","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1039\/b416943c","article-title":"Enantiomeric cannabidiol derivatives: Synthesis and binding to cannabinoid receptors","volume":"3","author":"Hanus","year":"2005","journal-title":"Organic Biomolecular Chemistry"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0360","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.2042-7158.1982.tb04670.x","article-title":"Effect of (+)- or (\u2212)-enantiomers of fenfluramine or norfenfluramine on nutrient selection by rats","volume":"34","author":"Hirsch","year":"1982","journal-title":"Journal of Pharmacy and Pharmacology."},{"key":"10.1016\/j.pharmthera.2025.108808_bb0365","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/clpt.1990.207","article-title":"The influence of age and gender on the stereoselective metabolism and pharmacokinetics of methyl phenobarbital in humans","volume":"48","author":"Hooper","year":"1990","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0370","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.pharmthera.2011.03.008","article-title":"Serotonin receptors and heart valve disease--it was meant 2B","volume":"132","author":"Hutcheson","year":"2011","journal-title":"Pharmacolgy and Therapeutics"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0375","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2015.0403","article-title":"Cell chirality: Its origin and roles in left-right asymmetric development","volume":"371","author":"Inaki","year":"2016","journal-title":"Philosophical Transactions of the Royal Society B Biological Sciences"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0380","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1471-4159.1977.tb10721.x","article-title":"\u03b3-Vinyl-GABA (4-amino-hex-5-enoic acid), a new selective irreversible inhibitor of GABA-T: Effects on brain GABA metabolism in mice","volume":"29","author":"Jung","year":"1977","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0385","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1021\/jm030913e","article-title":"Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity","volume":"47","author":"Kenda","year":"2004","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0390","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1111\/epi.12866","article-title":"Oxcarbazepine and its active metabolite, (S)-licarbazepine, exacerbate seizures in a mouse model of genetic generalized epilepsy","volume":"56","author":"Kim","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0395","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2165\/00003088-200443020-00002","article-title":"Clinical pharmacokinetics of everolimus","volume":"43","author":"Kirchner","year":"2004","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0400","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/epi.16450","article-title":"Repurposed molecules for antiepileptogenesis: Missing an opportunity to prevent epilepsy?","volume":"61","author":"Klein","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0405","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/epi.13340","article-title":"Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment","volume":"57","author":"Klitgaard","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0410","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1517\/17460441.2.11.1537","article-title":"Levetiracetam: The first SV2A ligand for the treatment of epilepsy","volume":"2","author":"Klitgaard","year":"2007","journal-title":"Expert Opinion in Drug Discovery"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0415","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/S0090-9556(24)14953-7","article-title":"Role of human CYP2B6 in S-mephobarbital N-demethylation","volume":"27","author":"Kobayashi","year":"1999","journal-title":"Drug Metabolism and Disposition"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0420","first-page":"36","article-title":"Role of CYP2C19 in stereoselective hydroxylation of mephobarbital by human liver microsomes","volume":"29","author":"Kobayashi","year":"2001","journal-title":"Drug Metabolism and Disposition"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0425","doi-asserted-by":"crossref","unstructured":"Kobayashi, K., Morita, J., Chiba, K., Wanibuchi, A., Kimura, M., Irie, S., Urae, A., Ishizaki, T. (2004). Pharmacogenetic roles of CYP2C19 and CYP2B6 in the metabolism of R- and S-mephobarbital in humans. Pharmacogenetics14, 549\u2013556.","DOI":"10.1097\/01.fpc.0000114764.78957.22"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0430","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/clpt.1985.196","article-title":"Stereoselective mephobarbital hydroxylation segregates with mephenytoin hydroxylation","volume":"38","author":"Kupfer","year":"1985","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0435","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/0028-3908(86)90214-5","article-title":"Differential effect of gamma-vinyl GABA and valproate on GABA-transaminase from cultured neurons and astrocytes","volume":"25","author":"Larsson","year":"1986","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0440","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.neuropharm.2005.08.016","article-title":"Stereoselective effects of the novel anticonvulsant lacosamide against 4-AP induced epileptiform activity in rat visual cortex in vitro","volume":"50","author":"Lees","year":"2006","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0445","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000137588","article-title":"Anticonvulsant effects of the (\u2212) and (+) isomers of cannabidiol and their dimethylheptyl homologs","volume":"24","author":"Leite","year":"1982","journal-title":"Pharmacology"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0450","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1016\/S0968-0896(01)00204-8","article-title":"Functionalized amino acid anticonvulsants: Synthesis and pharmacological evaluation of conformationally restricted analogues","volume":"9","author":"LeTiran","year":"2001","journal-title":"Bioorganic and Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0455","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/j.1552-4604.1983.tb01799.x","article-title":"Pharmacokinetics of stiripentol in normal man: Evidence of nonlinearity","volume":"23","author":"Levy","year":"1983","journal-title":"Journal Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0460","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1007\/s11064-021-03358-2","article-title":"Efficacy of fenfluramine and norfenfluramine enantiomers and various antiepileptic drugs in a zebrafish model of Dravet syndrome","volume":"46","author":"Li","year":"2021","journal-title":"Neurochemical Research"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0465","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S0090-9556(25)08746-X","article-title":"Stereoselective metabolism and pharmacokinetics of racemic methylphenobarbital in humans","volume":"17","author":"Lim","year":"1989","journal-title":"Drug Metabolism and Disposition"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0470","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1432-1033.1977.tb11410.x","article-title":"4-Amino-hexenoic acid, a selective catalytic inhibitor of 4-aminobutyric acid aminotransferases in mammalian brain","volume":"74","author":"Lipper","year":"1977","journal-title":"European Journal of Biochemistry"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0475","article-title":"In silico drug repurposing pipeline using deep learning and structure-based approaches in epilepsy","volume":"14","author":"Lv","year":"2024","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0480","doi-asserted-by":"crossref","first-page":"9861","DOI":"10.1073\/pnas.0308208101","article-title":"The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam","volume":"101","author":"Lynch","year":"2004","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0485","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/epi.12610","article-title":"The case for medical marijuana in epilepsy","volume":"55","author":"Maa","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0490","article-title":"In vitro evaluation of fenfluramine and norfenfluramine as victims of drug interactions","volume":"10","author":"Martin","year":"2022","journal-title":"Pharmacology Research and Perspectives"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0495","article-title":"In vitro evaluation suggests fenfluramine and norfenfluramine are unlikely to act as perpetrators of drug interactions","volume":"10","author":"Martin","year":"2022","journal-title":"Pharmacology Research and Perspectives"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0500","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1021\/jm900141j","article-title":"Pharmaceutical \u201cgold\u201d from neurostablizing agents: Topiramate and successor molecules","volume":"52","author":"Maryanoff","year":"2009","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0505","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1021\/acsmedchemlett.6b00176","article-title":"Phenotypic assessment and the discovery of topiramate","volume":"7","author":"Maryanoff","year":"2016","journal-title":"ACS Medicinal Chemistry Letters"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0510","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1021\/jm00388a023","article-title":"Anticonvulsant O-alkyl sulfamates. 2,3:4,5-Bis-O-(1-methylethylidene)- \u03b2-D-fructopyranose sulfamate and related compounds","volume":"30","author":"Maryanoff","year":"1987","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0515","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.2165\/00003088-200342120-00002","article-title":"Clinical pharmacokinetics of oxcarbazepine","volume":"42","author":"May","year":"2003","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0520","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/j.1528-1167.2006.00459.x","article-title":"Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and the puerperium","volume":"47","author":"Mazzucchelli","year":"2006","journal-title":"Epilepsia"},{"issue":"Suppl. 3","key":"10.1016\/j.pharmthera.2025.108808_bb0525","first-page":"S5","article-title":"Oxcarbazepine: Mechanisms of action","volume":"35","author":"McLean","year":"1994","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0530","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1021\/acs.jmedchem.3c02239","article-title":"Chirality of new drug approvals (2013\u22122022): Trends and perspectives","volume":"67","author":"McVicker","year":"2024","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0535","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0014-2999(83)90620-9","article-title":"Anticonvulsant action in mice with sound-induced seizures of the optical isomers of y-vinyl-GABA","volume":"89","author":"Meldrum","year":"1983","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e18920","article-title":"Anticonvulsant effects of cenobamate in chemically and electrically induced seizure models in rodents","volume":"9","author":"Melnick","year":"2023","journal-title":"Heliyon"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0545","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/BF00427333","article-title":"Anorectic effect of fenfluramine isomers and metabolites: Relationship between brain levels and in vitro potencies on serotonergic mechanisms","volume":"85","author":"Mennini","year":"1985","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0550","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/bdd.266","article-title":"The pharmacokinetics of ethosuximide enantiomers in the rat","volume":"22","author":"Mifsud","year":"2001","journal-title":"Biopharmaceutics and Drug Disposition"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0555","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/chir.530070312","article-title":"Chiral aspects of the metabolism of ethosuximide","volume":"7","author":"Millership","year":"1995","journal-title":"Chirality"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0560","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/bdd.454","article-title":"Chiral aspects of the human metabolism of ethosuximide","volume":"26","author":"Millership","year":"2005","journal-title":"Biopharmaceutics and Drug Disposition"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0565","doi-asserted-by":"crossref","first-page":"8968","DOI":"10.1016\/j.bmc.2008.08.055","article-title":"Synthesis and anticonvulsant activities of N-benzyl (2R)-2-acetamido-3-oxysubstituted propionamide derivatives","volume":"16","author":"Morieux","year":"2008","journal-title":"Bioorganic and Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0570","first-page":"127","article-title":"Plasma vigabatrin enantiomer ratios in adults and children","volume":"30","author":"Nagarajan","year":"1993","journal-title":"Clinical and Experimental Neurology"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0575","doi-asserted-by":"crossref","first-page":"85","DOI":"10.59566\/IJBS.2006.2085","article-title":"Chiral drugs: An overview","volume":"2","author":"Nguyen","year":"2006","journal-title":"International Journal of Biomedical Sciences"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0580","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0014-2999(91)90438-V","article-title":"Characterization of tiagabine (NO-328), a new potent and selective GABA uptake inhibitor","volume":"196","author":"Nielsen","year":"1991","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0585","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.nurt.2006.11.003","article-title":"Ganaxolone","volume":"4","author":"Nohria","year":"2007","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0590","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0014-2999(95)00436-O","article-title":"The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes","volume":"286","author":"Noyer","year":"1995","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0595","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107866","article-title":"Fenfluramine repurposing from weight loss to epilepsy: What we do and do not know","volume":"226","author":"Odi","year":"2021","journal-title":"Pharmacology and Therapeutics"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0600","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/jcph.1309","article-title":"Proposition of a minimal effective dose of vigabatrin for the treatment of infantile spasms using pediatric and adult pharmacokinetic data","volume":"59","author":"Ounissi","year":"2019","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0605","series-title":"CBD: What does the science say?","first-page":"11","author":"Parker","year":"2022"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0610","doi-asserted-by":"crossref","first-page":"61","DOI":"10.14581\/jer.17012","article-title":"Cannabinoids in the treatment of epilepsy: Hard evidence at last?","volume":"7","author":"Perucca","year":"2017","journal-title":"Journal of Epilepsy Research"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0615","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s40263-023-01027-2","article-title":"New GABA-targeting therapies for the treatment of seizures and epilepsy: I. Role of GABA as a modulator of seizure activity and recently approved medications acting on the GABA system","volume":"37","author":"Perucca","year":"2023","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0620","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.eplepsyres.2011.05.013","article-title":"Pharmacokinetics of eslicarbazepine acetate at steady-state inadults with partial-onset seizures","volume":"96","author":"Perucca","year":"2011","journal-title":"Epilepsy Research"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0625","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S1474-4422(23)00151-5","article-title":"Drug resistance in epilepsy","volume":"22","author":"Perucca","year":"2023","journal-title":"Lancet Neurology"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0630","author":"Pharmacogenomics Knowledgebase (Pharm GKB)"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0635","doi-asserted-by":"crossref","unstructured":"Qiu, S., Tehrani, K.A, Sergeyev, S., Bultinck, P., Herrebout, W., & Mathieu, B. (2016). Stereochemistry of the brivaracetam diastereoisomers. Chirality 28, 215\u2013225.","DOI":"10.1002\/chir.22558"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0640","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1177\/01926233231179147","article-title":"Retinal and systemic toxicity of vigabatrin is driven by the S-enantiomer in the long Evans rat","volume":"51","author":"Rasmussen","year":"2023","journal-title":"Toxicologic Pathology"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0645","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/B978-0-444-53630-3.00008-7","article-title":"Neurosteroids: Endogenous role in the human brain, their therapeutic potentials","volume":"186","author":"Reddy","year":"2010","journal-title":"Progress in Brain Research"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0650","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1365-2125.1990.tb03772.x","article-title":"Pharmacokinetics of the individual enantiomers of vigabatrin (gamma-vinyl GABA) in epileptic children","volume":"30","author":"Rey","year":"1990","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0655","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.eplepsyres.2019.01.002","article-title":"Pharmacokinetic evaluation of vigabatrin dose for the treatment of refractory focal seizures in children using adult and pediatric data","volume":"150","author":"Rodrigues","year":"2019","journal-title":"Epilepsy Research"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0660","doi-asserted-by":"crossref","unstructured":"Schoonjans, A-M., Roosens, L., Dewals, W., Paelinck, B. P., & Ceulemans, B. (2022). Therapeutic drug monitoring of fenfluramine in clinical practice: Pharmacokinetic variability and impact of concomitant antiseizure medications. Epilepsia 63, 686\u2013696.","DOI":"10.1111\/epi.17162"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0665","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1161\/01.CIR.102.23.2836","article-title":"Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications","volume":"102","author":"Rothman","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0670","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1067\/mhj.2002.126733","article-title":"Effect of fenfluramine-derivative diet pills on cardiac valves: A meta-analysis of observational studies","volume":"144","author":"Sachdev","year":"2002","journal-title":"American Heart Journal"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0675","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/BF00428109","article-title":"Memory retrieval deficits: Activation by etiracetam, a nootropic drug","volume":"68","author":"Sara","year":"1980","journal-title":"Psychopharmacology"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2025.108808_bb0680","first-page":"19S","article-title":"Clinical pharmacology of vigabatrin","volume":"27","author":"Schechter","year":"1989","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0685","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0024-3205(00)00432-X","article-title":"Stereoselective inhibition of dopaminergic activity by gamma-vinyl GABA in response to cocaine and nicotine: A PET microdialysis study","volume":"66","author":"Schiffer","year":"2000","journal-title":"Life Sciences"},{"issue":"Suppl. 5","key":"10.1016\/j.pharmthera.2025.108808_bb0690","first-page":"S47","article-title":"Oxcarbazepine: Preclinical anticonvulsant profile and putative mechanisms of action","volume":"35","author":"Schmutz","year":"1994","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0695","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1007\/BF00965769","article-title":"Stereoselective uptake of the GABA-transaminase inhibitors gamma-vinyl GABA and gamma-acetylenic GABA into neurons and astrocytes","volume":"11","author":"Schousboe","year":"1986","journal-title":"Neurochemical Research"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0700","doi-asserted-by":"crossref","first-page":"769","DOI":"10.3109\/00498258609043567","article-title":"The metabolism of 14C-oxcarbazepine in humans","volume":"8","author":"Schutz","year":"1986","journal-title":"Xenobiotica"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0705","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1016\/S0041-1345(98)00587-9","article-title":"Chemical modification of rapamycin: The discovery of SDZ RAD","volume":"30","author":"Sedrani","year":"1998","journal-title":"Transplantation Proceedings"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0710","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1517\/17425255.1.3.377","article-title":"Screening the receptorome reveals molecular targets responsible for drug-induced side effects: Focus on \u201cfen-phen\u201d","volume":"1","author":"Setola","year":"2005","journal-title":"Expert Opinion on Drug Metabolism and Toxicology"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0715","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1528-1157.1994.tb02459.x","article-title":"Topiramate: Preclinical evaluation of a structurally novel anticonvulsant","volume":"35","author":"Shank","year":"1994","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0720","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0920-1211(92)90088-B","article-title":"Comparative anticonvulsant potency and pharmacokinetics of (+)- and (\u2212)-enantiomers of stiripentol","volume":"12","author":"Shen","year":"1992","journal-title":"Epilepsy Research"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0725","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S1059-1311(00)90467-9","article-title":"Effective and safe but forgotten: Methsuximide in intractable epilepsies in childhood","volume":"10","author":"Sigler","year":"2001","journal-title":"Seizure"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0730","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/epi.13994","article-title":"The prescribable drugs with efficacy in experimental epilepsies (PDE3) database for drug repurposing research in epilepsy","volume":"59","author":"Sivapalarajah","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmthera.2025.108808_bib836","first-page":"75","article-title":"Racemates: Towards a New Year resolution? trends in","volume":"9","author":"Smith","year":"1988","journal-title":"Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0735","doi-asserted-by":"crossref","first-page":"1192022","DOI":"10.3389\/fphar.2023.1192022","article-title":"Fenfluramine: A plethora of mechanisms?","volume":"14","author":"Sourbron","year":"2023","journal-title":"Frontiers in Pharmacology"},{"issue":"Pt B","key":"10.1016\/j.pharmthera.2025.108808_bb0740","article-title":"New paradigms for the treatment of pediatric monogenic epilepsies: Progressing toward precision medicine","volume":"131","author":"Specchio","year":"2022","journal-title":"Epilepsy and Behaviour"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0745","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1212\/WNL.24.3.250","article-title":"Plasma levels of methsuximide and N-desmethylmethsuximide during methsuximide therapy","volume":"42","author":"Strong","year":"1974","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0750","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/j.1528-1157.1995.tb02576.x","article-title":"A review of the preclinical pharmacology of tiagabine: A potent and selective anticonvulsant GABA uptake inhibitor","volume":"36","author":"Suzdak","year":"1995","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0755","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S0090-9556(25)07513-0","article-title":"Metabolic chiral inversion of stiripentol in the rat. II. Influence of route of administration","volume":"22","author":"Tang","year":"1994","journal-title":"Drug Metabolism and Disposition"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0760","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0920-1211(93)90070-N","article-title":"Potent and stereospecific anticonvulsant activity of 3-isobutyl GABA relates to in vitro binding at a novel site labeled by tritiated gabapentin","volume":"14","author":"Taylor","year":"1993","journal-title":"Epilepsy Research"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0765","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/00007691-199412000-00016","article-title":"Ethosuximide enantiomers in pregnancy and lactation","volume":"16","author":"Tomson","year":"1994","journal-title":"Therapeutic Drug Monitoring"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0770","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1046\/j.1365-2125.1998.t01-1-00693.x","article-title":"Vigabatrin: Placental transfer in vivo and excretion into breast milk of the enantiomers","volume":"45","author":"Tran","year":"1998","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0775","first-page":"154","article-title":"Stiripentol. A novel antiepilepletic drug","volume":"576","author":"Trojnar","year":"2005","journal-title":"Pharmacological Reports"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0780","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(00)02047-X","article-title":"Chiral switches","volume":"355","author":"Tucker","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0785","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1046\/j.1365-2125.1996.00495.x","article-title":"Pharmacokinetics of the individual enantiomers of vigabatrin in neonates with uncontrolled seizures","volume":"42","author":"Vauzelle-Kervroedan","year":"1996","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0790","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/BF00174514","article-title":"Effects of nootropic drugs in a scopolamine-induced amnesia model in mice","volume":"95","author":"Verloes","year":"1988","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0795","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/00007691-199009000-00018","article-title":"Nonstereoselective disposition of ethosuximide in humans","volume":"12","author":"Vill\u00e9n","year":"1990","journal-title":"Therapeutic Drug Monitoring"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0800","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1053\/cp.1999.v66.103170001","article-title":"Enantioselective pharmacokinetics of 10-hydroxy-carbazepine following oral administration of oxcarbazepine to healthy Chinese subjects","volume":"66","author":"Volosov","year":"1999","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0805","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.456","article-title":"Preclinical tissue distribution and metabolic correlations of vigabatrin, an antiepileptic drug associated with potential use-limiting visual field defects","volume":"7","author":"Walters","year":"2019","journal-title":"Pharmacology Research and Perspectives"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0810","first-page":"49","article-title":"Enzymologie pharmaco-ceIlulaire du mode d'action du Stiripentol au cours de I'epilepsie cardiazolique. I. Problemes generaux et activites respiratoires","volume":"2","author":"Wegmann","year":"1977","journal-title":"Rivista di Istochimica Normale e Patologica (suppl.)"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0815","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1152\/jn.00856.2002","article-title":"Vigabatrin induces tonic inhibition via GABA transporter reversal without increasing vesicular GABA release","volume":"89","author":"Wu","year":"2003","journal-title":"Journal of Neurophysiology"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0820","unstructured":"Xenon Pharmaceuticals Inc. (2024) Method for treating epilepsy, European patent 3829558, granted July 2, 2024."},{"key":"10.1016\/j.pharmthera.2025.108808_bb0825","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2024.148991","article-title":"Differential toxic and antiepileptic features of vigabatrin raceme and its enantiomers","volume":"1838","author":"Xu","year":"2024","journal-title":"Brain Research"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0830","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/S0090-9556(25)07512-9","article-title":"Metabolic chiral inversion of stiripentol in the rat: Mechanistic studies","volume":"22","author":"Zhang","year":"1994","journal-title":"Drug Metabolism and Disposition"},{"key":"10.1016\/j.pharmthera.2025.108808_bb0835","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsps.2023.101934","article-title":"Pharmacokinetics and tissue distribution of vigabatrin enantiomers in rats","volume":"32","author":"Zheng","year":"2024","journal-title":"Saudi Pharmaceutical Journal"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725825000208?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725825000208?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T14:58:17Z","timestamp":1741100297000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725825000208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":168,"alternative-id":["S0163725825000208"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2025.108808","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"From barbiturates to ganaxolone: The importance of chirality in drug development and in understanding the actions of old and new antiseizure medications","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2025.108808","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108808"}}